Celldex Therapeutics reported $402.96M in Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Agenus AGEN:US $ 456.17M 14.87M
Amgen AMGN:US $ 59294M 98M
Applied Genetic Technologies AGTC:US $ 87.19M 5.18M
Aptinyx Inc APTX:US $ 92.31M 14.35M
Biocept BIOC:US $ 61.94M 1.53M
Bristol Myers Squibb BMY:US $ 100357M 2677M
Celldex Therapeutics CLDX:US $ 402.96M 21.08M
Cytrx CYTR:US 6.56M 2.16M
Glaxosmithkline GSK:US $ 89045M 644M
Immunogen IMGN:US $ 422.3M 59.41M
Merrimack Pharmaceuticals MACK:US $ 14.06M 584K
Nektar Therapeutics NKTR:US $ 861.99M 162.13M
Newlink Genetics NLNK:US $ 85.45M 7.74M
Northwest Biotherapeutics NWBO:US 27.52M 3.14M
Seattle Genetics SGEN:US $ 3630.34M 13.65M